1,921 million decreased by 7% compared to the previous year. It derived from: • Revenues from sales and services of medical device business for the year 2019 were Baht 1,798 million decreased by 3% in
(minute/s Postpaid Prepaid Blended VOU (GB/data s Postpaid Prepaid Blended Device Penetrat 4G‐handset Fixed Broadban FBB subscri FBB net add FBB ARPU ( 1H17 Snap For 1H17, AIS (excluding IC
% -2.4% Prepaid 113 92 86 -24% -6.5% Blended 138 118 112 -19% -5.1% VOU (GB/data sub/month) Postpaid 14.4 16.6 17.0 18% 2.3% Prepaid 10.3 11.1 13.8 34% 23% Blended 11.4 12.7 14.7 29% 16% Device Penetration
appropriate by Dhipaya Bodin as a joint venture. It will benefit potential shareholders in the medical device and distribution business. The current production and distribution line is Blood Line with a
center, cyber security, ICT solutions, and 5G services. EBITDA is expected to grow by low-single digit, driven by better revenue momentum and controlled costs while ensuring proper capital allocation to
improved following on-going cost optimization and FY17 guidance maintained. AIS reported 3Q17 EBITDA of Bt17,589mn, +15% YoY and +2.8% QoQ, mainly due to revenue growth and controlled SG&A. YTD, AIS spent
% margin, largely from controlled handset subsidy, improve revenue momentum, and cost efficiency. Service revenue (excluding IC) increased 4.9% YoY supported by both mobile and fixed broadband segments
lower network traffic with TOT and change in IC rate effective from Jan- 22. Device & SIM card sales reported Bt9,270mn, decreasing -4.3% YoY and -32% QoQ. QoQ drop was mainly from high seasonal sales of
เครื่องแม่ข่าย (server) และอุปกรณ์ที่ใช้ปฏิบัติงาน (endpoint) ข้อ 8.5 การกำหนดนโยบายและมาตรการรักษาความปลอดภัยสำหรับการใช้งานอุปกรณ์ส่วนตัว (bring your own device : BYOD) ข้อ 8.9 การประเมินช่องโหว่ทางเทคนิค